EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CRISPR/Cas9-based genome-wide screening for metastasis ability identifies FCGR1A regulating the metastatic process of ovarian cancer by targeting LSP1

Yingying Qi, Weiyan Zhu, Kexin Mo, Hui Jiang

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05837-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Yingying Qi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, CRISPR-Cas Systems. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the open research funds of the Sixth Affiliated Hospital of Guangzhou Medical University, Science and Technology Projects in Guangzhou, Science and Technology Program of Guangzhou, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastasis is a main cause of death from ovarian cancer (OC). Identifying key markers involved in OC metastasis can aid in the effective detection of early postoperative metastasis. However, the role of FCGR1A in OC metastasis has yet to be fully established. A genome-wide CRISPR/Cas9-based screening system was used to identify regulatory factors involved in metastasis.

Methods

The expression of FCGR1A and LSP1 in ovarian cancer cell lines was examined by quantitative real-time polymerase chain reaction (qRT‒PCR). The functions of FCGR1A and LSP1 in OC cell migration, invasion and proliferation were determined using wound healing, Transwell invasion and CKK-8 assays. A transcription-activated library was used to identify the potential downstream genes of FCGR1A. FCGR1A expression was detected by immunohistochemistry and the immunity risk score (IRS) scores were calculated.

Results

FCGR1A was upregulated in OC cells compared with normal ovarian cells. Downregulation of FCGR1A inhibited metastasis, proliferation and epithelial–mesenchymal transition (EMT) progression in OC cells in vitro and intraperitoneal metastasis in vivo. Moreover, downregulation of FCGR1A was accompanied by decreased LSP1 expression. Overexpression of LSP1 partially reversed the tumor suppressive effect of FCGR1A downregulation. Higher FCGR1A expression was related to metastasis, higher grade, higher stage, and lymph node metastasis in OC. Survival analysis suggested that the group with higher FCGR1A expression had a lower tumor-free survival rate and a lower overall survival rate than did the group with low FCGR1A expression.

Conclusions

FCGR1A enhances OC metastasis by regulating LSP1, and FCGR1A is associated with poor prognosis, suggesting that FCGR1A is a potential predictive factor for detecting early postoperative metastasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsCRISPR-Cas SystemsFemaleHumansMiceAnimalsCell Line, TumorReceptors, IgGCell ProliferationNeoplasm MetastasisMice, NudeCell MovementEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticCell Adhesion MoleculesMice, Inbred BALB CMicrofilament Proteins

Stichwörter der Autor:innen

CRISPR/Cas9 screeningFCGR1ALSP1MetastasisOvarian cancer

Substanzen

LSP1 protein, humanReceptors, IgGCell Adhesion MoleculesMicrofilament Proteins

Autor:innen und Institutionen

  • Department of Gynecology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Department of Obstetrics and Gynecology, The Sixth Affiliated Hospital of Guangzhou Medical University, QingYuan, China.
  • Department of Gynecology and Obstetrics, Guangdong Second Hospital of Traditional Chinese Medicine, Guangzhou, China. jhui5833@163.com.

Förderung

  • the open research funds of the Sixth Affiliated Hospital of Guangzhou Medical University
  • Science and Technology Projects in Guangzhou
  • Science and Technology Program of Guangzhou, China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Guangdong Provincial Second Hospital of Traditional Chinese Medicine Scientific research innovation Foundation

Zitieren

APA

Qi, Y., Zhu, W., Mo, K., & Jiang, H. (2024). CRISPR/Cas9-based genome-wide screening for metastasis ability identifies FCGR1A regulating the metastatic process of ovarian cancer by targeting LSP1. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05837-9

Vancouver

Qi Y, Zhu W, Mo K, Jiang H. CRISPR/Cas9-based genome-wide screening for metastasis ability identifies FCGR1A regulating the metastatic process of ovarian cancer by targeting LSP1. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05837-9

BibTeX
@article{Qi2024,
  author = {Qi, Yingying and Zhu, Weiyan and Mo, Kexin and Jiang, Hui},
  title = {CRISPR/Cas9-based genome-wide screening for metastasis ability identifies FCGR1A regulating the metastatic process of ovarian cancer by targeting LSP1},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05837-9}
}
Kostenlos starten →